Cerebrospinal Fluid Concentration of the RET Inhibitor Pralsetinib: A Case Report [PDF]
Case Reports in Oncology, 2023 Introduction: Pralsetinib is used to treat metastatic RET fusion-positive non-small cell lung cancer. Preclinical studies of pralsetinib have shown blood-brain barrier (BBB) penetration and intracranial activity.
Loek A.W. De Jong +2 more
doaj +8 more sources
Impact of P‐gp inhibition on systemic exposure of pralsetinib and dosing considerations [PDF]
Clinical and Translational ScienceA study to determine the impact of cyclosporine (Neoral), an inhibitor of P‐gp, on the pharmacokinetics of pralsetinib (trade name GAVRETO®) was conducted in 15 healthy adult volunteers.
Julia Suchomel +8 more
doaj +4 more sources
Exploring the Impact of Hepatic Impairment on Pralsetinib Pharmacokinetics [PDF]
PharmaceuticsPralsetinib is a kinase inhibitor indicated for the treatment of metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer.
Kit Wun Kathy Cheung +7 more
doaj +4 more sources
Intracranial Response to Selpercatinib After Pralsetinib-Induced Disease Progression in Rearranged During Transfection Fusion-Positive Non-Small-Cell Lung Cancer: Case Report [PDF]
JTO Clinical and Research ReportsRET fusion-positive NSCLC accounts for 1% to 2% of lung carcinoma cases. Although two Food and Drug Administration–approved selective RET inhibitors, pralsetinib, and selpercatinib, have revealed efficacy in managing RET fusion-positive NSCLC, this case ...
Illaa Smesseim, MD +2 more
doaj +4 more sources
A Locally Advanced NSCLC Patient Harboring a Rare KIF13A-RET Fusion Benefited from Pralsetinib: A Case Report [PDF]
Current OncologyThe application of adjuvant treatment has significantly enhanced the survival of patients with resectable non-small cell lung cancer (NSCLC) carrying driver gene mutations.
Zenghao Chang +4 more
doaj +4 more sources
Case report: Recurrent lung infections following treatment with pralsetinib for an elderly patient with RET-fusion positive NSCLC [PDF]
Frontiers in Oncology, 2022 Patients with RET fusions represent 1-2% of all cases of non-small cell lung cancer (NSCLC), the majority of whom are younger, and are extremely rare in the elderly.
Li An +9 more
doaj +2 more sources
Re-challenging pralsetinib following recovery from pneumocystis jirovecii pneumonia in a lung cancer patient: a Case Report [PDF]
Frontiers in PharmacologyBackgroundPneumocystis jirovecii pneumonia (PJP), an opportunistic infection, is commonly observed in immunocompromised individuals, particularly those with cancer, and is known for its significant morbidity and mortality rates.
Zhe Zhao +4 more
doaj +2 more sources
Genomics review of selective RET inhibitors sensitivity in thyroid cancer clinical trials [PDF]
American Journal of Medical Genetics Part C: Seminars in Medical Genetics, Volume 199, Issue 3, Page 228-238, September 2025.Producción CientíficaRET gene is a driver of thyroid cancer (TC) tumorigenesis. The incidence of TC has increased worldwide in the last few decades, both in medullary and follicular-derived subtypes.
Capdevilla, Jaume +5 more
core +2 more sources
The RET inhibitor pralsetinib suppresses TMZ-resistant glioma growth by regulating spermine production [PDF]
Frontiers in PharmacologyObjectiveGlioma is the most common malignant tumor of the central nervous system and is characterized by altered cellular metabolism. Although temozolomide (TMZ)-based adjuvant treatment has improved overall patient survival, clinical outcomes remain ...
Lingyun Ma +11 more
doaj +2 more sources
Precision oncology for RET-related tumors [PDF]
Frontiers in Oncology, 2022 Aberrant activation of the RET proto-oncogene is implicated in a plethora of cancers. RET gain-of-function point mutations are driver events in multiple endocrine neoplasia 2 (MEN2) syndrome and in sporadic medullary thyroid cancer, while RET ...
Antonella Verrienti +7 more
doaj +3 more sources